MedTrace Logo

Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)

NCT03057470 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-02-20

No results posted yet for this study

Summary

The overall objective of this study is to investigate the glycemic response of a 0%, 50%, 100% and 150% bolus insulin correction (based on personal insulin correction factor) of post-exercise hyperglycemia in physically active adults with type 1 diabetes (T1D) using multiple daily injections (MDI) in a controlled, but clinically representative, experimental setting.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

50% bolus insulin correction

Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia

DRUG

100% bolus insulin correction

Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia

DRUG

150% bolus insulin correction

Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia

OTHER

0% bolus insulin correction

Patients will receive no bolus insulin correction for post-exercise hyperglycemia

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • LMC Diabetes & Endocrinology Ltd.

    lead OTHER

Principal Investigators

  • Ronnie Aronson, MD · LMC Diabetes & Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057470 on ClinicalTrials.gov